Jaguar Health Adds Six-Fold Equity Plan Share Increase Ahead of November 6 Vote
JAGX is trading near its 52-week low of $2 (3.0% above the low) on light trading volume (0.1× avg).
Summary
Jaguar Health supplemented its October 8 proxy to disclose a board-approved six-fold increase in the 2014 Stock Incentive Plan share reserve, lifting the pool to 2,273,154 shares if Proposal 3 passes at the November 6 special meeting.
Key Events · Corporate Governance and Compliance · JAGX
-
Six-Fold Equity Plan Reserve Increase
On October 28, 2026, the board approved a six-fold increase in shares available under the 2014 Plan, effective immediately following the November 6, 2026 Special Meeting.
-
Pool Size Depends on Proposal 3
If stockholders approve Proposal 3, the reserve becomes 2,273,154 shares (378,859 x 6); if not, 4,260 shares (710 x 6). Either way, the ISO cap is set at 163,998 shares (27,333 x 6).
-
Series R Conversion Drives Adjustment
The adjustment offsets the Series R Preferred dividend, which converts 5-for-1 into common on November 2, 2026 and would otherwise shrink the plan's relative size to about one-sixth of its intended 14% of fully diluted shares.
-
November 6 Special Meeting Vote
Proposal 3 and the broader proxy proposals, including up to 92.9% dilution from CVP debt/preferred exchanges, go to holders at the November 6, 2026 special meeting.
Analysis · JAGX · Life Sciences
The board unilaterally multiplied the 2014 Stock Incentive Plan reserve by six on October 28, 2026, effective right after the November 6 special meeting, to offset the share count blow-up from the Series R Preferred dividend that converts 5-for-1 on November 2. If shareholders approve Proposal 3, the plan reserve goes from 378,859 shares to 2,273,154; if they reject it, the reserve is still multiplied to 4,260 shares from 710. Either way the compensation pool is being resized without a separate shareholder vote on the multiplier itself, which is a governance point worth noting for a company already asking holders to accept up to 92.9% dilution and sitting near its 52-week low with a going-concern warning previously disclosed in the August 19 10-Q.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 30.9% of the 1649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $2.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9M. The 52-week trading range was $2.00 to $1,102.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.